Loading stock data…
Obsidian Therapeutics, Inc. (OBX)
$18.73+1.91 (+11.36%)
Market ClosedLast close Sep 8
Obsidian Therapeutics, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$20.28M↑ | -$26.60M |
| Net Income | -$19.63M↑ | -$24.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for adva...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.16B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.15%
Volume
Today's trading volume
599,437
Recent News
Obsidian Therapeutics (OBX) Stock Dropped, So What Is Behind The Attention Now?
Obsidian Therapeutics (OBX) is back in focus after enrolling the first patient in a registration enabling cohort for its Agni-01 trial of amsoki-cel in advanced melanoma, along with fresh index and capital structure moves. Investors are weighing funding flexibility and potential dilution alongside changing views on the company’s risk profile and growth potential following the latest trial milestone and index inclusion.
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls